Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HRA Pharma has been granted marketing authorization for its next generation emergency contraceptive, ellaOne (ulipristal acetate), by the European Commission. ellaOne will be launched and marketed throughout Europe, directly by HRA Pharma in the UK, Germany, Italy and France, and via partner companies elsewhere.
Subscribe to our email newsletter
The company plans to file for marketing approvals worldwide under the trademarks ellaOne and ella, and continue to research pharmaceutical developments in the field of reproductive health that are better adapted to women’s lifestyles.
Dr. Erin Gainer, CEO of HRA Pharma, said: “this milestone is testimony to emergency contraception as a real therapeutic need and to the potential of ulipristal acetate as a viable solution.
Our goal is to ensure that ellaOne is available to the millions of women who might need it, and we plan to put our sales and marketing infrastructure as well as our privileged partnerships into action to accompany this roll-out, he added.